Cellular and molecular gastroenterology and hepatology

Drug Activation of Nrf2 May Improve Experimental Fatty Liver Disease and Scarring

Updated

Abstract

TBE-31 treatment reversed insulin resistance and substantially decreased liver steatosis in high-fat plus fructose-fed wild-type mice.

  • Activation of Nrf2 was associated with improved glucose metabolism in wild-type mice fed a high-fat plus fructose diet.
  • TBE-31 treatment led to decreased liver fat and reduced expression of genes related to fat production.
  • Increased expression of genes involved in fat breakdown and lipoprotein formation was observed in treated wild-type mice.
  • TBE-31 treatment resulted in lower levels of endoplasmic reticulum stress, inflammation, and markers of liver damage.
  • No beneficial effects of TBE-31 were seen in Nrf2-null mice, indicating the necessity of Nrf2 for these outcomes.

Simplified

Full Text

We can’t show the full text here under this license.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free